Royal Bank of Canada (RY) reported an 11% increase in earnings for the third quarter driven by benefits from North American interest rates and client volume growth as well as solid results across all geographies in Capital Markets. The diversified financial services company’s stock rose 0.32% in the premarket session.
Net income increased 11% to C$3.11 billion, while EPS grew 14% to C$2.10. The quarter’s strong performance also reflects relatively stable credit quality with provision for credit losses (PCL) on impaired loans ratio of 17 basis points and PCL ratio on loans of 23 bps.
Income from Personal & Commercial Banking rose by 8%, on improved deposit spreads resulting from higher Canadian interest rates, solid growth in Canadian residential mortgages, commercial lending, and deposit products. Income from Wealth Management grew by 19%, on positive equity market performance and client activity, as well as strong volume growth, higher interest rates, and a lower effective tax rate.
Income from Insurance declined 2% due to higher costs supporting sales growth and client service activities, while that from Capital Markets increased by 14%, primarily due to higher revenue in Corporate and Investment Banking and Global Markets.
Adjusted EPS were C$2.14, up from C$1.89 a year ago. Revenue rose by 9% to C$11 billion, helped by higher revenue growth in Personal & Commercial Banking and Wealth Management. Expenses rose by 6% due to its continued investments to support business growth, including technology and digital initiatives.
The 90-day Active Mobile users increased 18% from a year ago to 3.7 million, resulting in a 22% increase in mobile sessions. Digital adoption rate increased by 4 points year-over-year to 49.4%.
Shares of Royal Bank of Canada ended Tuesday’s regular session down 0.56% at $78.48 on the NYSE. The stock had risen over 7% for the past year, while it had fallen more than 3% for the year-to-date.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on